Articles By Anuja Singh
Is Mayo Clinic’s NVIDIA Blackwell-Powered DGX SuperPOD the Next Leap in AI-Driven Clinical Innovation?
Key Highlights NVIDIA Blackwell Infrastructure: High-Performance Compute for Healthcare AIThe NVIDIA DGX SuperPOD system delivers state-of-the-art, scalable AI…
By
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus Panel the Breakthrough for Fast, Decentralized…
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million in new federal…
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI…
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
Could GSK and Hengrui’s $12B Alliance Set a New Standard in China-Originated Drug Collaborations?
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…
Is Mayo Clinic’s NVIDIA Blackwell-Powered DGX SuperPOD the Next Leap in AI-Driven Clinical Innovation?
Key Highlights NVIDIA Blackwell Infrastructure: High-Performance Compute for Healthcare AIThe NVIDIA DGX SuperPOD system delivers state-of-the-art, scalable AI…
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus Panel the Breakthrough for Fast, Decentralized…
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million in new federal…
Is Aidoc’s $150M Bet on CARE™ and aiOS™ Resetting the Future of Clinical AI…
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
Could GSK and Hengrui’s $12B Alliance Set a New Standard in China-Originated Drug Collaborations?
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…